Substance use disorder (SUD) affects millions of individuals and presents unique clinical, ethical and interpersonal challenges in dental practice. This program provides dental professionals with the tools to recognize the oral manifestations of SUD, manage treatment compassionately, and navigate the complexities of care coordination, relapse risk and stigma. From the dental implications of “new” opioids, to synthetic cannabinoids and emerging illicit use of licit medications, participants will explore evidence-based approaches to providing non-judgmental, effective dental care to this vulnerable population.

Pediatric patients are frequently prescribed medications that can significantly influence their oral health, behavior, and dental treatment planning. This program provides an in-depth review of the most commonly prescribed medications for children and their implications in dental care. Participants will learn how to recognize medication-related oral side effects, manage dental complications, and communicate effectively with caregivers and prescribing physicians to optimize treatment outcomes. Designed for all dental professionals, this program emphasizes interprofessional collaboration and evidence-based strategies tailored to pediatric patients.

Local anesthesia is foundational to pain control in dentistry, but effective and safe use requires a deep understanding of pharmacology, patient-specific considerations and evolving clinical protocols. Ideal for both dentists and hygienists, this course provides an in-depth review of local anesthetics used in dental practice and bridges pharmacology and therapeutics to enhance patient safety, comfort and outcomes.

Diabetes and its systemic complications are often compounded by multiple co-morbid conditions. This course offers an overview of diabetes mellitus, current treatment options, and the connection between diabetes and oral-systemic disease. Special focus is given to emerging therapies, including single-action GLP-1 (glucagon-like peptide-1) agonists such as Ozempic (semaglutide) and dual-action GLP-1/GIP (gastric inhibitory polypeptide) agonists such as Mounjaro (tirzepatide), highlighting their expanding roles in managing both diabetes and obesity for improved overall health outcomes.